PIVI’s Work with Mongolia
Mongolia joined PIVI in 2016. Mongolia’s first vaccination campaign prioritized healthcare workers and staff in emergency agencies. The campaign was highly successful, as 100% of the 45,000 doses were administered successfully. With PIVI support, Mongolia developed an animated television short advocating for vaccination that has been broadcast on five TV channels and embedded on three websites.
Mongolia hosted an advocacy meeting with key decision-makers from the ministry of health, the national immunization technical advisory group, the National Influenza Center of Mongolia, and the National Department of Communicable Diseases to discuss the impact of flu vaccination. Mongolia completed a national survey of adverse events following flu immunization (AEFI). They conducted an active follow up of 6,943 people, 15% of the total number of people who were recipients of Protein Science’s Flublok vaccine, the first recombinant protein influenza vaccine approved by the U.S. FDA for persons 18 and older. The country has also completed a nationwide survey of factors affecting vaccine uptake pregnant women and the general public who accept and decline flu vaccination. Mongolia is planning to conduct a formal, enhanced surveillance of adverse events following immunization among pregnant women recipients of Flublok vaccine.